We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Not sitting idly by while one of its most successful painkillers prepares for generic launch, Purdue Pharma has petitioned the FDA to withhold final approval for a generic version of OxyContin until generic firms implement appropriate risk management plans (RMPs) and has filed its notice to appeal a recent court decision.